Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

lidermed s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

genfar del peru s.a.c. - droguerÍa - fosfato disodico de betametasona; - solucion inyectable - por mililitro 1.00 mg - - betametasona

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

straumann group peru s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

dident s.r.l. -

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ferrer internacional s.a. - enalapril maleato; nitrendipino - comprimido - 10 mg/20 mg - enalapril maleato 10 mg; nitrendipino 20 mg - enalapril y nitrendipino

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - esclerosis múltiple - inmunosupresores selectivos - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, crónica - antivirales para uso sistémico - victrelis está indicado para el tratamiento de la infección por genotipo 1 hepatitis crónica c (chc), en combinación con peginterferón alfa y ribavirina, en pacientes adultos con enfermedad hepática compensada que no están previamente no tratados o que han fallado terapia anterior.

Unión Europea - español - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Unión Europea - español - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unión Europea - español - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabina - leucemia-linfoma linfoblástico de células t precursoras - agentes antineoplásicos - nelarabine está indicado para el tratamiento de los pacientes con t-células de la leucemia linfoblástica aguda (lla-t) y de células t linfoma linfoblástico (t-lbl), cuya enfermedad no ha respondido o ha recaído después de tratamiento con al menos dos regímenes de quimioterapia. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.